Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Manitoba

$17,500.00

Determining mucosal biomarkers of HIV-risk in CAPRISA-004 trial participants utilizing a proteomics approach

EF 2013-14

Résumé
Per-coital rates of HIV transmission are low but heterogeneous; an incomplete understanding of why some individuals are infected more easily than others poses a major gap in the HIV literature. This proposal focuses on unraveling the mucosal host immunology that predicts HIV-1 infection in a large partially successful microbicide clinical trial using a systems biology based-approach. While utilizing HIV-1 infection as an endpoint prospectively is the optimal study design to infer causation, such studies are costly and time consuming, since the number of participants requiring follow-up is large. Nevertheless, more detailed studies in high-risk human cohorts represent the most biologically relevant context by which to assess the relationship between HIV acquisition and mucosal risk factors. New approaches are needed for HIV-1 prevention that do not require partner cooperation. Despite the emergence of several partially effective biomedical HIV prevention tools and declining global incidence, HIV-1 continues to spread with 2 million new infections per year, suggesting that a ‘prevention gap’ still exists for high-risk HIV uninfected individuals. The CAPRISA 004 trial of a tenofovir-based vaginal gel was the only microbicide trial that has demonstrated efficacy in preventing HIV-1 infection; with a modest 39% reduction in HIV-1 acquisition. Therefore there is an urgent need for continued research to understand HIV transmission in order to develop HIV prevention options that target HIV uninfected individuals. However the immunology of HIV transmission is very complex, and reductionist approaches used to date, focusing on pre-defined immune factors such as cytokines/chemokines, under-appreciates the complexity of the mucosal immune environment and is likely contributing to a lack of progress. Indeed, the mucosal immune system contains many hundreds of soluble immune factors which can modulate innate defense, including inflammation, immune activation, adaptive responses, and direct host defense against HIV. While many of these could be associated with HIV risk, studies to date have typically been quite narrow and/or underpowered. Our research team is proposing a novel systems biology based approach to answer this question by combining innovative proteomics-based tools specifically designed for studying mucosal immune systems in our lab, and access to a large unique HIV prevention trial cohort to understand this complex biological processes and factors which associate that predict HIV-susceptibility. This proposal will represent the first and most comprehensive systems biology analysis of mucosal samples from a large scale HIV prevention trial that uses HIV-infection as an endpoint. The identification of mucosal mediators underlying HIV-susceptibility will significantly increase our understanding of risk factors for HIV-1 infection.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
Manitoba, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
311891
Name
Perner Michelle
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Determining mucosal biomarkers of HIV-risk in CAPRISA-004 trial participants utilizing a proteomics approach
Programtype2
Studentship Programs
Orgnameinp2
University of Manitoba
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Female Genital Tract; Hiv Susceptibility; Innate Immunity; Proteomics; Soluble Factors
Abstract
Per-coital rates of HIV transmission are low but heterogeneous; an incomplete understanding of why some individuals are infected more easily than others poses a major gap in the HIV literature. This proposal focuses on unraveling the mucosal host immunology that predicts HIV-1 infection in a large partially successful microbicide clinical trial using a systems biology based-approach. While utilizing HIV-1 infection as an endpoint prospectively is the optimal study design to infer causation, such studies are costly and time consuming, since the number of participants requiring follow-up is large. Nevertheless, more detailed studies in high-risk human cohorts represent the most biologically relevant context by which to assess the relationship between HIV acquisition and mucosal risk factors. New approaches are needed for HIV-1 prevention that do not require partner cooperation. Despite the emergence of several partially effective biomedical HIV prevention tools and declining global incidence, HIV-1 continues to spread with 2 million new infections per year, suggesting that a ‘prevention gap’ still exists for high-risk HIV uninfected individuals. The CAPRISA 004 trial of a tenofovir-based vaginal gel was the only microbicide trial that has demonstrated efficacy in preventing HIV-1 infection; with a modest 39% reduction in HIV-1 acquisition. Therefore there is an urgent need for continued research to understand HIV transmission in order to develop HIV prevention options that target HIV uninfected individuals. However the immunology of HIV transmission is very complex, and reductionist approaches used to date, focusing on pre-defined immune factors such as cytokines/chemokines, under-appreciates the complexity of the mucosal immune environment and is likely contributing to a lack of progress. Indeed, the mucosal immune system contains many hundreds of soluble immune factors which can modulate innate defense, including inflammation, immune activation, adaptive responses, and direct host defense against HIV. While many of these could be associated with HIV risk, studies to date have typically been quite narrow and/or underpowered. Our research team is proposing a novel systems biology based approach to answer this question by combining innovative proteomics-based tools specifically designed for studying mucosal immune systems in our lab, and access to a large unique HIV prevention trial cohort to understand this complex biological processes and factors which associate that predict HIV-susceptibility. This proposal will represent the first and most comprehensive systems biology analysis of mucosal samples from a large scale HIV prevention trial that uses HIV-infection as an endpoint. The identification of mucosal mediators underlying HIV-susceptibility will significantly increase our understanding of risk factors for HIV-1 infection.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Perner, Michelle
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~